Global Alzheimer’s Disease Pipeline Review 2020: Stage of Development, Drug Target, MoA, RoA and Molecule Type

DUBLIN, Oct. 19, 2020 /PRNewswire/ — The «Alzheimer’s Disease – Pipeline Review, H2 2020» drug pipelines has been added to…

DUBLIN, Oct. 19, 2020 /PRNewswire/ — The «Alzheimer’s Disease – Pipeline Review, H2 2020» drug pipelines has been added to’s offering.

Research and Markets Logo

Alzheimer’s Disease – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Alzheimer’s Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer’s Disease (Central Nervous System) pipeline guide also reviews the key players involved in therapeutic development for Alzheimer’s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 21, 61, 77, 1, 4, 345, 134 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 2, 100 and 47 molecules, respectively.

Alzheimer’s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer’s Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer’s Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Topics Covered:


  • Alzheimer’s Disease – Overview
  • Alzheimer’s Disease – Therapeutics Development

Alzheimer’s Disease – Therapeutics Assessment

Alzheimer’s Disease – Companies Involved in Therapeutics Development

Alzheimer’s Disease – Drug Profiles

Alzheimer’s Disease – Dormant Projects

  • Alzheimer’s Disease – Discontinued Products
  • Alzheimer’s Disease – Product Development Milestones


Companies Mentioned

  • 1st Bio Therapeutics Inc
  • 2A Pharma AB
  • 4P-Pharma SAS
  • AB Science SA
  • Abaxy Sprl
  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accuitis Pharmaceuticals Inc
  • Acelerox LLC
  • Acelot Inc
  • Actinogen Medical Ltd
  • Acumen Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Adocia SAS
  • ADRx Inc
  • Aerobyx LLC
  • AfaSci Inc
  • Affichem SA
  • Aibios Co Ltd
  • Alector Inc
  • Alfasigma SpA
  • Alkahest Inc
  • Alkermes Plc
  • AlphaCognition Inc
  • Alsonex Pty Ltd
  • ALSP Inc
  • Alzamend Neuro Inc
  • AlzeCure Pharma AB
  • Alzheon Inc
  • Alzhyme Pty Ltd
  • Alzinova AB
  • AlzProtect SAS
  • Alzyn LLC
  • Amyloid Solution Inc
  • Amylon LLC
  • Amylyx Pharmaceutical Corp
  • Anavex Life Sciences Corp
  • Ankar Pharma SL
  • Annovis Bio Inc
  • Antoxerene Inc
  • Anven AlzDx Inc
  • Aphios Corp
  • Apodemus AB
  • Apollo Therapeutics LLC
  • Applied Research using OMIC Sciences SL
  • Aprinoia Therapeutics Inc
  • AptaBio Therapeutics Inc
  • Araclon Biotech SL
  • Archer Pharmaceuticals Inc
  • AriBio
  • ArmaGen Inc
  • Armgo Pharma Inc
  • Artery Therapeutics Inc
  • Arvinas Inc
  • Asceneuron SA
  • Asdera LLC
  • AskAt Inc
  • Asklepios BioPharmaceutical Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Astrocyte Pharmaceuticals Inc
  • AstronauTx Ltd
  • Athira Pharma Inc
  • ATP Biopharm
  • Augustus BioTarget Inc
  • Auransa Inc
  • Aurin Biotech Inc
  • Auritec Pharmaceuticals Inc
  • Autifony Therapeutics Ltd
  • Autophagy Neurotherapeutics Inc
  • Avanti Biosciences Inc
  • Avidin Biotechnology Ltd
  • Avineuro Pharmaceuticals Inc
  • Axon Neuroscience SE
  • Axxam SpA
  • AZTherapies Inc
  • BCWorld Pharm Co Ltd
  • Benuvia Therapeutics Inc
  • Berg LLC
  • BeyondBio Inc
  • Bio-Pharm Solutions Co Ltd
  • BioArctic AB
  • Biogen Inc and many more

For more information about this drug pipelines report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets

Laura Wood, Senior Manager   

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904

Fax (outside U.S.): +353-1-481-1716

Cision View original content:

SOURCE Research and Markets